Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejcts.2007.12.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and tolerability of losartan to treat recessive dystrophic epidermolysis bullosa in children (REFLECT): an open-label, single-arm, phase 1/2 trial.
EClinicalMedicine
November 2024
Department of Dermatology, Medical Center- University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Article Synopsis
- Recessive dystrophic epidermolysis bullosa (RDEB) is a severe skin condition that causes blisters and other complications, and this study tested the safety of losartan, a medication that may slow its progression.
- The study was a phase 1/2 trial involving children aged 2-16 with confirmed RDEB, focusing on identifying any serious side effects of losartan over a treatment period of 10 months.
- Primary safety concerns monitored included severe drops in blood pressure, allergic reactions, and changes in potassium levels, along with evaluating the drug's effectiveness through various clinical scores.
Variations in Adverse Events Typology Following E-Cigarette Use: The Role of Preexisting Medical Conditions.
Subst Use Misuse
November 2024
San Diego Supercomputer Center, San Diego, CA, USA.
Background: Electronic cigarettes (e-cigarettes) are often marketed as safer alternatives to traditional smoking, yet evidence suggests potential health risks, especially among vulnerable populations. This study examines the immediate adverse events following e-cigarette use in individuals with preexisting health conditions to better understand these risks.
Methods: We conducted a STROBE-compliant observational study to identify specific preexisting medical conditions that may increase the risk of adverse events following e-cigarette use.
When the Blisters Reach the Heart: An Uncommon Case of Cardiac Involvement in Bullous Pemphigoid.
Cureus
August 2024
Internal Medicine, Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, IND.
Article Synopsis
- Bullous pemphigoid is a skin disease mostly seen in older people, which can sometimes cause heart problems.
- A 46-year-old woman with high blood pressure got a serious heart issue called complete heart block while also having bullous pemphigoid.
- Doctors treated her by putting in a special device to help her heart and giving her medicine to control her skin condition.
Concomitant oxidative haemolysis and methaemoglobinaemia following inhaled nitric oxide in a patient with G6PD deficiency.
BMJ Case Rep
August 2024
Division of Hematology, The Johns Hopkins Hospital, Baltimore, Maryland, USA
Article Synopsis
- A man in his 50s was hospitalized with acute respiratory distress syndrome and right heart failure, requiring intubation and inhaled nitric oxide (iNO) treatment to help his heart function.
- He developed acute anemia, diagnosed as methaemoglobinaemia and oxidative haemolysis, which showed specific blood abnormalities.
- After conservative treatment and eventually stopping iNO, both issues improved, leading to a confirmation of glucose-6-phosphate dehydrogenase (G6PD) deficiency four months later, illustrating a rare occurrence of these conditions linked to iNO use in someone with G6PD deficiency.
Interest of therapeutic plasmapheresis in a chronic hemodialysis patient with severe bullous pemphigoid.
J Clin Apher
June 2024
Service Néphrologie dialyse Aphérèse, Hôpital Universitaire de Nîmes, CHU Carémeau, France.
Article Synopsis
- Bullous pemphigoid is a common autoimmune blistering disease primarily affecting older adults, often linked to serious health conditions like diabetes and heart disease.
- It involves the body producing autoantibodies that attack proteins in the skin, leading to painful blisters and a high mortality rate within the first year.
- A case study is presented of a diabetic patient on hemodialysis with severe bullous pemphigoid who was successfully treated with double filtration plasmapheresis, which helped eliminate the need for systemic steroids.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!